Eli Lilly (LLY)
(Delayed Data from NYSE)
$762.66 USD
+8.49 (1.13%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $762.65 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Net Sales: Trulicity (Dulaglutide / GLP-1 Fc / LY2189265): Total
- 7,132.60
- 7,439.70
- 6,471.90
- 5,068.10
- 4,127.80
- Revenue - Line of Business (LOBR)
- Net Sales: Humalog [$M]
- 1,663.30
- 2,060.60
- 2,453.00
- 2,625.90
- 2,820.70
- Revenue - Line of Business (LOBR)
- Net Sales: Taltz (Ixekizumab / LY2439821 / IL-17) - Total
- 2,759.60
- 2,482.00
- 2,212.80
- 1,788.50
- 1,366.40
- Revenue - Line of Business (LOBR)
- Net Sales: Alimta [$M]
- 217.50
- 927.70
- 2,061.40
- 2,329.90
- 2,115.80
- Revenue - Line of Business (LOBR)
- Net Sales: Jardiance (Empagliflozin/BI 10773): Total
- 2,744.70
- 2,066.00
- 1,490.80
- 1,153.80
- 944.20
- Revenue - Line of Business (LOBR)
- Net Sales: Verzenio- Total
- 3,863.40
- 2,483.50
- 1,349.90
- 912.70
- 579.70
- Revenue - Line of Business (LOBR)
- Net Sales: Humulin [$M]
- 852.10
- 1,019.40
- 1,222.60
- 1,259.60
- 1,290.10
- Revenue - Line of Business (LOBR)
- Net Sales: Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor: Total
- 922.60
- 830.50
- 1,115.10
- 638.90
- 426.90
- Revenue - Line of Business (LOBR)
- Net Sales: Cyramza (Ramucirumab /IMC-1121B): Total
- 974.70
- 971.40
- 1,033.00
- 1,032.60
- 925.10
- Revenue - Line of Business (LOBR)
- Net Sales: Basaglar (LY2963016 / Insulin Glargine): Total
- 728.30
- 760.40
- 892.50
- 1,124.40
- 1,112.60
- Revenue - Line of Business (LOBR)
- Net Sales: Oncology: Retevmo
- 253.60
- 191.90
- 114.70
- --
- --
- Revenue - Line of Business (LOBR)
- Net Sales: Oncology: Tyvyt
- 393.40
- 293.30
- 418.10
- --
- --
- Revenue - Line of Business (LOBR)
- Net Sales: Diabetes: Other
- 143.10
- 80.80
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Net Sales: Oncology: Other Oncology
- 180.70
- 140.80
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Net sales: Other - Other - Total
- 107.60
- 154.20
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Net Sales: Diabetes: Mounjaro -Total
- 5,163.10
- 482.50
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Net Sales: Neurosciences
- 2,878.50
- 1,546.20
- 1,898.50
- 1,831.30
- 1,722.90
- Revenue - Line of Business (LOBR)
- Net Sales: Oncology [$M]
- 6,658.30
- 5,666.10
- 5,741.30
- 5,319.30
- 4,614.40
- Revenue - Line of Business (LOBR)
- Net Sales: Cialis [$M]
- 381.50
- 587.30
- 718.40
- 607.10
- 890.50
- Revenue - Line of Business (LOBR)
- Net Sales: Cymbalta [$M]
- 242.60
- 283.30
- 581.50
- 767.70
- 725.40
- Revenue - Line of Business (LOBR)
- Net Sales: Immunology
- 3,797.60
- 3,344.60
- 3,360.80
- 2,461.90
- 1,793.30
- Revenue - Line of Business (LOBR)
- Net Sales: Neuroscience: Other Neuroscience
- 227.40
- 124.90
- 95.40
- --
- --
- Revenue - Line of Business (LOBR)
- Net Sales: Forteo [$M]
- 533.20
- 613.10
- 801.90
- 1,046.30
- 1,404.70
- Revenue - Line of Business (LOBR)
- Net Sales: Erbitux [$M]
- 596.50
- 566.50
- 548.30
- 536.40
- 543.40
- Revenue - Line of Business (LOBR)
- Net Sales: Emgality (Galcanezumab) - US
- 482.20
- 462.80
- 434.50
- 618.20
- 7.70
- Revenue - Line of Business (LOBR)
- Net Sales: Emgality (Galcanezumab) - Total
- 678.30
- 650.90
- 577.20
- 362.90
- 162.50
- Revenue - Line of Business (LOBR)
- Net Sales: Emgality (Galcanezumab) - ROW
- 196.00
- 188.10
- 142.70
- 37.00
- 7.70
- Revenue - Line of Business (LOBR)
- Net Sales: Diabetes Total
- 19,667.50
- 14,464.80
- 13,188.10
- 11,834.40
- 11,132.10
- Revenue - Line of Business (LOBR)
- Net sales: Trajenta
- 386.90
- 383.70
- 372.50
- 358.50
- 590.60
- Revenue - Geographic (GEOR)
- Geographic Revenue: United States
- 21,791.00
- 18,190.00
- 16,811.00
- 14,229.30
- 12,722.60
- Revenue - Geographic (GEOR)
- Geographic Revenue: Europe
- 6,174.70
- 4,299.20
- 4,776.80
- 4,187.70
- 3,765.00
- Revenue - Geographic (GEOR)
- Geographic Revenue: Japan
- 1,672.60
- 1,747.30
- 2,367.00
- 2,583.10
- 2,547.60
- Revenue - Geographic (GEOR)
- Net Sales: US-Humalog [$M]
- 863.20
- 1,191.90
- 1,320.70
- 1,486.00
- 1,669.70
- Revenue - Geographic (GEOR)
- Net Sales: US-Alimta [$M]
- 72.90
- 543.70
- 1,233.90
- 1,265.00
- 1,219.50
- Revenue - Geographic (GEOR)
- Net Sales: US-Forteo [$M]
- 335.50
- 367.30
- 441.60
- 510.30
- 645.50
- Revenue - Geographic (GEOR)
- Geographic Revenue: Other foreign countries
- 2,946.20
- 2,852.00
- 2,702.20
- 2,422.70
- 2,344.90
- Revenue - Geographic (GEOR)
- Net Sales: Basaglar (LY2963016 / Insulin Glargine) - ROW
- 285.20
- 289.70
- 304.20
- 282.10
- 64.90
- Revenue - Geographic (GEOR)
- Net Sales: International-Humalog [$M]
- 800.20
- 868.70
- 1,132.30
- 1,140.00
- 1,151.00
- Revenue - Geographic (GEOR)
- Net Sales: International-Alimta [$M]
- 144.60
- 384.00
- 827.50
- 1,065.00
- 896.40
- Revenue - Geographic (GEOR)
- Net Sales: International-Forteo [$M]
- 197.70
- 245.80
- 360.30
- 536.00
- 759.10
- Revenue - Geographic (GEOR)
- Net Sales: Jardiance (Empagliflozin/BI 10773) - ROW
- 1,144.20
- 871.50
- 683.50
- 533.00
- 138.50
- Revenue - Geographic (GEOR)
- Net Sales: Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor: US
- 225.50
- 148.20
- 324.10
- 63.80
- 42.20
- Revenue - Geographic (GEOR)
- Net Sales: Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor: ROW
- 697.20
- 682.30
- 791.00
- 49.00
- 28.10
- Revenue - Geographic (GEOR)
- Net Sales: Taltz (Ixekizumab / LY2439821 / IL-17) - US
- 1,831.60
- 1,724.60
- 1,542.40
- 1,288.50
- 1,016.80
- Revenue - Geographic (GEOR)
- Net Sales: Taltz (Ixekizumab / LY2439821 / IL-17) - ROW
- 928.00
- 757.40
- 670.40
- 500.00
- 63.70
- Revenue - Geographic (GEOR)
- Net Sales: Basaglar (LY2963016 / Insulin Glargine) - US
- 443.10
- 470.70
- 588.30
- 842.30
- 876.20
- Revenue - Geographic (GEOR)
- Net Sales: Verzenio- US
- 2,509.00
- 1,653.20
- 834.90
- 618.20
- 124.90
- Revenue - Geographic (GEOR)
- Net Sales: Verzenio- ROW
- 1,354.30
- 830.30
- 515.00
- 294.40
- 124.90
- Revenue - Geographic (GEOR)
- Net Sales: Diabetes- United States (U.S.)
- 14,780.80
- 9,911.10
- 8,719.30
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Diabetes- Outside U.S
- 4,886.80
- 4,553.70
- 4,468.80
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Oncology- United States (U.S.)
- 3,797.00
- 3,218.10
- --
- 2,792.10
- 2,608.50
- Revenue - Geographic (GEOR)
- Net Sales: Oncology- Outside U.S
- 2,861.30
- 2,448.10
- --
- 2,527.20
- 2,005.90
- Revenue - Geographic (GEOR)
- Net Sales: Immunology- United States (U.S.)
- 2,057.90
- 1,892.80
- 1,881.80
- 1,372.30
- 1,059.00
- Revenue - Geographic (GEOR)
- Net Sales: Immunology- Outside U.S
- 1,739.60
- 1,451.80
- 1,479.00
- 1,089.60
- 734.30
- Revenue - Geographic (GEOR)
- Net Sales: Neuroscience- United States (U.S.)
- 696.00
- 612.40
- 614.80
- 487.30
- 356.50
- Revenue - Geographic (GEOR)
- Net Sales: Neuroscience- Outside U.S
- 2,182.50
- 933.80
- 1,283.70
- 1,344.00
- 1,366.40
- Revenue - Geographic (GEOR)
- Net Sales: Oncology: Tyvyt - Outside U.S.
- 393.40
- 293.30
- 418.10
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Oncology: Erbitux - U.S.
- 528.90
- 500.10
- 361.00
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Oncology: Erbitux - Outside U.S.
- 67.60
- 66.40
- 47.40
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Oncology: Other Oncology - U.S.
- 33.70
- 27.20
- 120.10
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Oncology: Other Oncology - Outside U.S.
- 147.00
- 113.60
- 210.70
- --
- --
- Revenue - Geographic (GEOR)
- Revenue to unaffiliated customers: Outside U.S.
- 12,333.10
- 10,351.30
- 7,708.10
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Diabetes: Other - U.S.
- 84.70
- 39.90
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Diabetes: Other - Outside U.S.
- 58.40
- 40.90
- --
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Other: Other -U.S.
- 35.80
- 88.70
- --
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Other: Other -Outside U.S
- 71.80
- 65.50
- --
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Diabetes: Mounjaro -U.S.
- 4,834.20
- 366.60
- --
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Diabetes: Mounjaro -Outside U.S.
- 328.90
- 115.90
- --
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Other Neuroscience: Other -U.S.
- 75.10
- 85.50
- 102.00
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: Other Neuroscience- Outside U.S.
- 152.30
- 189.60
- 207.50
- --
- --
- Revenue - Geographic (GEOR)
- Net Sales: US-Cialis [$M]
- 26.10
- 35.20
- 10.60
- 61.80
- 231.70
- Revenue - Geographic (GEOR)
- Net Sales: US-Cymbalta [$M]
- 30.70
- 33.70
- 38.70
- 42.10
- 49.60
- Revenue - Geographic (GEOR)
- Net Sales: US-Humulin [$M]
- 610.10
- 730.20
- 832.90
- 866.40
- 879.70
- Revenue - Geographic (GEOR)
- Net Sales: International-Cialis [$M]
- 355.30
- 552.10
- 707.90
- 545.40
- 658.80
- Revenue - Geographic (GEOR)
- Net Sales: International-Cymbalta [$M]
- 211.90
- 249.60
- 542.80
- 725.60
- 675.80
- Revenue - Geographic (GEOR)
- Net Sales: International-Humulin [$M]
- 242.00
- 289.20
- 389.60
- 393.20
- 410.40
- Revenue - Geographic (GEOR)
- Net Sales: Jardiance (Empagliflozin/BI 10773) - US
- 1,600.40
- 1,194.50
- 807.30
- 620.80
- 565.90
- Revenue - Geographic (GEOR)
- Net Sales: Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - ROW
- 1,699.20
- 1,750.90
- 1,557.60
- 1,232.00
- 232.10
- Revenue - Geographic (GEOR)
- Net Sales: Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - US
- 5,433.30
- 5,688.80
- 4,914.40
- 3.84
- 3,155.20
- Revenue - Geographic (GEOR)
- Net Sales: Cyramza (Ramucirumab /IMC-1121B) - ROW
- 572.40
- 620.00
- 674.80
- 650.80
- 79.20
- Revenue - Geographic (GEOR)
- Geographic Revenue: China
- 1,539.70
- 1,452.80
- 1,661.40
- 1,116.90
- 939.40
- Revenue - Geographic (GEOR)
- Net Sales: Cyramza (Ramucirumab /IMC-1121B) - US
- 402.30
- 351.40
- 358.10
- 381.90
- 335.30